FindTrial
Sign In

THE EFFECTS OF LEVOSIMENDAN ON ARTERIALL STIFFNESS IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE

THE EFFECTS OF LEVOSIMENDAN ON ARTERIALL STIFFNESS IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-007518-13-SI
Enrollment
Unknown
Registered
2007-12-19
Start date
2007-12-20
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced chronic heart failure MedDRA version: 9.1 Level: LLT Classification code 10008908 Term: Chronic heart failure

Interventions

Trade Name: Simdax Pharmaceutical Form: Concentrate for solution for infusion

Sponsors

University Medical Centre Ljubljana
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age above 18 years 2. At least a 3-month history of advanced heart failure symptoms (NYHA III) 3. Evidence of impaired left ventricular ejection fraction (EF=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. Advanced Renal insuficiency (Creatinine clearance of less than 30 ml/min) 2. Advanced liver failure (liver enzymes > 5x ULN) 3. Hipotension (systolic blood pressure 100/min)

Design outcomes

Primary

MeasureTime frame
Main Objective: The aim of the present study is to investigate the effects of levosimendan infusion on conduit vessel stiffness in patients with advanced chronic heart failure.;Secondary Objective: ;Primary end point(s): Augmentation index (as a measure of arterial stiffness) as measured by pulse wave analysis—

Countries

Slovenia

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026